PHAT vs. IGMS, CALT, AVBP, STOK, AVTE, GHRS, OLMA, CDMO, ZYME, and PHAR
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include IGM Biosciences (IGMS), Calliditas Therapeutics AB (publ) (CALT), ArriVent BioPharma (AVBP), Stoke Therapeutics (STOK), Aerovate Therapeutics (AVTE), GH Research (GHRS), Olema Pharmaceuticals (OLMA), Avid Bioservices (CDMO), Zymeworks (ZYME), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical preparations" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
Phathom Pharmaceuticals has higher revenue and earnings than IGM Biosciences. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 56.9% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Phathom Pharmaceuticals received 5 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 67.33% of users gave Phathom Pharmaceuticals an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
Phathom Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -11,255.25%. Phathom Pharmaceuticals' return on equity of 0.00% beat IGM Biosciences' return on equity.
In the previous week, IGM Biosciences had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for IGM Biosciences and 11 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.79 beat IGM Biosciences' score of 0.36 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.
Phathom Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
Phathom Pharmaceuticals presently has a consensus price target of $22.00, suggesting a potential upside of 110.73%. IGM Biosciences has a consensus price target of $17.89, suggesting a potential upside of 78.89%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than IGM Biosciences.
Summary
Phathom Pharmaceuticals beats IGM Biosciences on 11 of the 18 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
